^
    Back
    Association details:
    Biomarker:EGFR wild-type + ALK wild-type
    Cancer:Non Small Cell Lung Cancer
    Drug:AiTan (rivoceranib) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Prospective, single-center, observational clinical study for Camrelizumab in the second-line treatment of advanced EGFR and ALK wild-type non-small cell lung cancer

    Excerpt:
    ...EGFR and ALK wild-type non-small cell lung cancer patients by genetic testing; 5. ...
    Trial ID:
    ChiCTR1900027220
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Onco Targets Ther
    Title:

    Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma

    Published date:
    01/18/2017
    Excerpt:
    Herein, we report three cases of advanced NSCLC with epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative status, wherein the patients showed partial response to apatinib. Moreover, the three patients have achieved a progression-free survival of 2.8, 5.8, and 6 months, respectively.
    DOI:
    10.2147/OTT.S126613